← Eichor
Study identifier: NCT07143149 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China

Condition: Ischemic Stroke · Transient Ischemic Attack (TIA)  ·  Sponsor: Beijing Tiantan Hospital

PhaseNA
Planned participants4000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.

This description comes directly from the study's public registry record.

Talk to the study team

Jie Xu  ·  59975672  ·  xujie@ncrcnd.org.cn

Aichun Cheng  ·  13240768490  ·  aichuncheng0822@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07143149